Skip to Main Content

Advertisement

Issue Archive

Table of Contents

BLOOD COMMENTARIES

BLOOD SPOTLIGHT

In this timely Blood Spotlight, Barta et al summarize for the practicing hematologist the strengths and limitations of current data on brentuximab vedotin–based treatment in peripheral T-cell lymphoma (PTCL).

HOW I TREAT

This issue’s How I Treat article offers valuable insights to clinicians caring for patients with congenital antithrombin deficiency and is likely to be especially helpful for clinicians who only see a few cases in their career.

CLINICAL TRIALS AND OBSERVATIONS

The results of a recent randomized control trial challenged the use of a platelet count of 50 × 109/L as the threshold for prophylactic transfusions in preterm neonates, indicating lower rates of severe bleeding or death with use of 25 × 109/L as the trigger point. Here, the authors further analyze trial data and conclude that the 25 × 109/L threshold can be adopted for all preterm neonates, irrespective of predicted baseline outcome risk.

This article reports the outcomes of a clinical trial of CD28-containing CD19-specific chimeric antigen receptor (CAR) T cells in pediatric, adolescent, and young adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL). Minimal disease burden at entry and use of high-dose cyclophosphamide conditioning are reported to be associated with more favorable outcomes.

LYMPHOID NEOPLASIA

A deep dive into genomic aberrations in 37 new diagnoses of primary mediastinal B-cell lymphoma (PMBL) reveals a surprisingly high number of driver mutations as well as genetic and epigenetic explanations for immune evasion by the tumor.

MYELOID NEOPLASIA

The authors describe recurrent novel insertion/deletion mutations in the JH2 domain of JAK2 occurring in patients with eosinophilia as a prominent feature of their myeloproliferative neoplasms. Remarkably, 2 of the patients with a specific mutation (Leu583-Ala586DelInsSer) meet the criteria for both chronic eosinophilic leukemia and polycythemia vera, suggesting that this may be a distinct overlap syndrome.

THROMBOSIS AND HEMOSTASIS

Currently, we have insufficient understanding of venous thromboembolism in cancer patients. In this article, the authors reveal a novel mechanism for colon cancer-associated venous thrombosis using a murine model.

LETTER TO BLOOD

BLOOD WORK

Close Modal

or Create an Account

Close Modal
Close Modal

Advertisement

X